PTC Therapeutics has completed its acquisition of ST-920, a one-time gene therapy for Fabry disease from Sangamo Therapeutics. The company plans to submit a rolling Biologics License Application (BLA) to the FDA for accelerated approval by Q4 2026. ST-920 has shown promise in clinical trials by enabling long-term enzyme production and reducing disease markers, potentially offering a durable alternative to chronic enzyme replacement therapy. This acquisition supports PTC's mission to develop transformative treatments for rare diseases.
PTC Therapeutics' acquisition of ST-920 gene therapy is the subject, with Pluang market data providing context. As of Sep 22, 2026 01:32 WIB, 62 of 95 priced Health-sector US stocks rose while 32 fell. Notable movers include Agilent Technologies Inc at USD 162.66 with a 3.96% increase and a typical hold time of 38 days on Pluang.
Two directors of Equitable Holdings sold shares recently, with Bertram L. Scott selling 2,780 shares and Craig C. MacKay selling 2,000 shares. Meanwhile, institutional investors showed mixed activity: Engineers Gate Manager LP drastically cut its hol...
Shares of Greenland-linked mining companies surged following a new U.S.-Denmark-Greenland security agreement that boosted investor interest in Greenland's mineral resources. Greenland Mines Ltd. jumped over 229%, while Critical Metals Corp. rose near...
Biotech stocks and leveraged ETFs were the biggest losers in the market, with Cue Biopharma dropping 23.7% despite positive Phase 2 clinical results. Leveraged ETFs tied to AMD, Strategy, and Novo Nordisk also saw sharp declines due to their daily-re...
Priority Technology Holdings is being taken private in a $1.6 billion deal led by its Chairman and CEO, Thomas Priore. The acquisition price is $8.05 per share, matching the analyst price target set by Lake Street, which downgraded the stock to 'Hold...
General Mills is set to report its Q3 2026 earnings with an expected 16.3% decline in earnings per share to $0.72 and revenue forecast around $4.35 billion, down from last year. Despite these declines, the company reaffirmed its full-year adjusted EP...
